Article Information
Published By
History
- Received April 28, 2026
- Accepted August 13, 2026
- Published online September 23, 2026.
Copyright & Usage
Copyright: © 2026, The Authors This work is licensed under the Creative Commons Attribution-NonCommercial 4.0 International License.
Author Information
Funding
Young Talents Program of Sun Yat-sen University Cancer Center
YTP-SYSUCC-0096 to H. Zhou
This work was supported by a grant from the Young Talents Program of Sun Yat-sen University Cancer Center (Grant No. YTP-SYSUCC-0096 to H. Zhou).
In this issue
Jump to section
- Article
- Defining the later-line treatment landscape
- BL-B01D1-303 in later-line NPC: established efficacy and unresolved issues
- Iza-bren in later-line NPC: managing hematologic toxicity and refining patient selection
- Rationale for an EGFR × HER3 bispecific ADC and its limitations
- ADC selection in R/M NPC: beyond response rates
- Predictive biomarkers and treatment sequencing for ADCs in NPC: unresolved issues
- Later-line NPC in the ADC era: what comes next?
- Conclusions
- Conflict of interest statement
- Author contributions
- References
- Figures & Data
- Info & Metrics
- References
Related Articles
Cited By...
- No citing articles found.